Ensign Peak Advisors
DNA icon

Ensign Peak Advisors’s Ginkgo Bioworks DNA Stock Holding History

Ensign Peak Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$931K Sell
93,979
-10,699
-10% -$89.5K ﹤0.01% 853
2026
Q1 		$642K Sell
104,678
-225,645
-68% -$1.88M ﹤0.01% 900
2025
Q4 		$2.74M Sell
330,323
-4,750
-1% -$51.1K ﹤0.01% 645
2025
Q3 		$4.89M Buy
335,073
+4,162
+1% +$49.8K 0.01% 592
2025
Q2 		$3.72M Buy
330,911
+4,500
+1% +$34.9K 0.01% 704
2025
Q1 		$1.86M Sell
326,411
-30
-0% -$306 ﹤0.01% 926
2024
Q4 		$3.21M Hold
326,441
– – 0.01% 777
2024
Q3 		$2.66M Buy
326,441
+280,000
+603% +$2.81M ﹤0.01% 831
2024
Q2 		$621K Sell
46,441
-35
-0.1% -$1.04K ﹤0.01% 1535
2024
Q1 		$2.16M Sell
46,476
-2,028
-4% -$105K ﹤0.01% 896
2023
Q4 		$3.28M Buy
48,504
+21,044
+77% +$1.29M 0.01% 730
2023
Q3 		$1.99M Sell
27,460
-45
-0.2% -$3.6K ﹤0.01% 837
2023
Q2 		$2.05M Sell
27,505
-58,581
-68% -$3.47M ﹤0.01% 868
2023
Q1 		$4.58M Sell
86,086
-74
-0.1% -$4.69K 0.01% 598
2022
Q4 		$5.82M Sell
86,160
-7,353
-8% -$676K 0.01% 528
2022
Q3 		$11.7M Hold
93,513
– – 0.03% 354
2022
Q2 		$8.9M Buy
93,513
+7,353
+9% +$897K 0.02% 401
2022
Q1 		$13.9M Sell
86,160
-7,353
-8% -$1.43M 0.03% 358
2021
Q4 		$31.1M Buy
93,513
+91,500
+4,545% +$43.5M 0.06% 250
2021
Q3 		$918K Buy
+2,013
New +$980K ﹤0.01% 1464

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Ensign Peak Advisors's DNA Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Ginkgo Bioworks (DNA) stake by 10% in Q2 2026, selling an estimated $89.5K and leaving 93,979 shares worth $931K. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Ensign Peak Advisors first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $31.1M in Q4 2021. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Ensign Peak Advisors held 93,979 shares of Ginkgo Bioworks worth $931K as of Q2 2026.
  • Ensign Peak Advisors sold 10,699 Ginkgo Bioworks shares in Q2 2026, an estimated $89.5K.
  • Ginkgo Bioworks made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #853 holding.
  • Ensign Peak Advisors first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
  • Ensign Peak Advisors's Ginkgo Bioworks position peaked at $31.1M in Q4 2021.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.